Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
PHILADELPHIA, May 05, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ: AKRO): Grabar Law Office is investigating whether certain officers and directors of Akero breached their...
-
PHILADELPHIA, March 24, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ: AKRO): Grabar Law Office is investigating whether certain officers and directors of Akero breached their...
-
PHILADELPHIA, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ: AKRO): Grabar Law Office is investigating whether certain officers and directors of Akero breached their...
-
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, June 17, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Akero Therapeutics, Inc....
-
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, June 11, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Akero Therapeutics, Inc....
-
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, June 06, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Akero Therapeutics, Inc....
-
Robbins LLP is Investigating Allegations that Akero Therapeutics, Inc. (AKRO) Misled Investors Regarding the Viability of its Trial Drug Candidate
-
Robbins LLP is Investigating Allegations that Akero Therapeutics, Inc. (AKRO) Misled Investors Regarding the Viability and Efficacy of its Trial Drug Candi
-
Robbins LLP is Investigating Allegations that Akero Therapeutics, Inc. (AKRO) Misled Investors Regarding the Viability and Efficacy of its Trial Drug Candi
-
Robbins LLP is Investigating Allegations that Akero Therapeutics, Inc. (AKRO) Misled Investors Regarding the Viability and Efficacy of its Trial Drug Candi